Cleanhill Partners Announces Partnership with CleanJoule to Drive Growth of Sustainable Aviation Fuel
Cleanhill Partners, a private equity firm pursuing investments in the energy transition sector that contribute to decarbonization, announced a partnership with CleanJoule LLC, the world’s leading producer of full-performance sustainable aviation fuels (SAF). The deal provides CleanJoule with the financial, strategic and operational resources to accelerate the commercialization of its technology – advancing meaningful efforts to slow climate change and addressing energy shortages predicted to disrupt the aviation industry within the next 30 years. The investment comes on the heels of Cleanhill’s partnership with KORE Power, Inc., the leading U.S.-based developer of battery cell technology for the electric transportation and energy storage industries.
“As decarbonization of the aviation sector continues to present a daunting technological challenge and mounting environmental imperative, we are thrilled to be able to partner with Cleanhill and advance our shared vision of creating cost-effective clean energy solutions that can be deployed today,” said Dr. Mukund Karanjikar, CEO of CleanJoule. “Having led the way in developing the industry’s most eco-friendly and commercially viable sustainable aviation fuel, CleanJoule is now very well-positioned to significantly expand its adoption and shorten the timeframes to achieving a greener global aviation industry.”
Dr. Karanjikar, who previously held innovation-focused roles at Technology Holding LLC and Chevron, has spent more than a decade developing the CleanJoule SAF technology, along with Dr. Ashok Joshi, a globally recognized, high-technology entrepreneur. Validated by the U.S. Department of Defense and U.S. Department of Energy, CleanJoule’s proprietary production process converts biomass into a superior SAF molecule along with a bio-derived rubber co-product, yielding the only carbon negative, zero-petroleum, full performance and 100 percent drop-in SAF that can be used in a variety of commercial aviation engines without modification.
Cleanhill co-founders and Managing Partners Ash Upadhyaya and Rakesh Wilson will join CleanJoule’s board of directors. Having previously served in leadership positions at KKR and Apollo, respectively, they bring decades of experience investing across the energy value chain.
“Cleanhill is laser-focused on partnering with companies such as CleanJoule that are solving large-scale decarbonization challenges with timely, commercially viable approaches,” said Upadhyaya and Wilson. “By rapidly scaling CleanJoule in collaboration with our industry partners, we’ll be advancing efforts of vital importance to the climate and global economy.”
Kirkland & Ellis LLP served as legal counsel to Cleanhill Partners.
About CleanJoule
CleanJoule is the world’s leading innovator of full-performance SAF, founded by a passionate and creative group of engineers, scientists and visionaries focused on aviation fuels, with the purpose of creating a sustainable planet, reducing global carbon emissions and ultimately combatting climate change. CleanJoule’s highly innovative technology allows it to harness existing energy from biomass and convert it to superior performance aviation fuel as well as bio-rubber that can be used in various consumer and commercial products. For more information, visit www.cleanjoule.com .
About Cleanhill Partners
Cleanhill Partners is a private equity firm pursuing investments in the energy transition sector that contribute to decarbonization. The firm invests in scalable businesses with visibility into revenues, earnings and cash flow growth, leveraging its thesis-driven approach and operational expertise to enhance value in each of our investments. The firm has offices in New York and Houston. To learn more, please visit www.cleanhillpartners.com .
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211101005195/en/
Contact information
Media Relations
Hannah Arnold, The LAKPR Group
harnold@lakpr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom